Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study

Table 3 Comparing early treatment discontinuation, treatment failure, and hematological AEs between matched treatment groups after adjusting imbalanced baseline variables

Treatment comparison	Platinum/Pemetrexed vs. Platinum/Docetaxel				Platinum/Pemetrexed vs. Platinum/Paclitaxel				Platinum/Pemetrexed vs. Platinum/Gemcitabine				Platinum/Pemetrexed vs. Platinum/Vinorelbine
Sample size	190				236				398				144
Outcome measures	OR	95% CI		P value*	OR	95% CI		P value*	OR	95% CI		P value*	OR	95% CI		P value*
Outcome measures	OR	Lower limit	Upper limit	P value*	OR	Lower limit	Upper limit	P value*	OR	Lower limit	Upper limit	P value*	OR	Lower limit	Upper limit	P value*
Early treatment discontinuation	0.239	0.106	0.536	*0.001*	0.389	0.210	0.722	*0.003*	0.340	0.215	0.538	*<0.001*	0.250	0.096	0.654	*0.005*
Treatment failure	0.377	0.189	0.750	*0.006*	0.257	0.134	0.493	*<0.001*	0.381	0.241	0.601	*<0.001*	0.265	0.109	0.647	*0.004*
Hematological AE
Neutropenia	2.140	0.738	6.205	0.161	0.695	0.352	1.372	0.295	1.300	0.789	2.143	0.304	0.360	0.132	0.981	*0.046*
Leukopenia	2.028	0.691	5.948	0.198	0.687	0.351	1.345	0.273	0.633	0.392	1.023	0.062	0.423	0.165	1.082	0.073
Anemia	0.905	0.404	2.026	0.808	0.618	0.326	1.174	0.142	0.357	0.221	0.576	*<0.001*	0.181	0.046	0.710	*0.014*
Thrombocytopenia	0.790	0.287	2.178	0.649	0.581	0.287	1.174	0.130	0.345	0.209	0.570	*<0.001*	1.105	0.413	2.960	0.842
Any hematological AE	0.687	0.327	1.442	0.321	0.508	0.274	0.943	*0.032*	0.383	0.229	0.642	*<0.001*	0.332	0.092	1.200	0.093

AE, adverse event; OR, odds ratio; CI, confidence interval. *: P values less than 0.05 were in bold to indicate significant differences.

ISSN: 1471-2407